News

Disclaimer

Disclaimer: MMV accepts no liability for the information presented here or for the consequences of any actions taken on the basis of this information.

1

Female laboratory technician performing microscopy

New single-dose medicine to prevent relapse of P. vivax malaria just approved in Peru

Mother holding young child in Thailand

GSK, MMV filing for Kozenis (tafenoquine) in paediatric populations with Plasmodium vivax malaria accepted by Australian Therapeutic Goods Administration

palm of hand face up holding dispersible tablets of tafenoquine

Study finds malaria drug can also prevent relapse in children

crowd of children looking directly at the camera

GSK and MMV present positive data on treatment for Plasmodium vivax malaria in children from 6 months up to 15 years of age

Webinar participants on screen

Event Highlights from the VivAccess Hosted Symposium at Virtual ASTMH: Accelerating New Tools for Radical Cure of Vivax Malaria from Clinical and Operational Research to Policy

Woman conducting training session - showing materials to participants

G6PD Operational Research in Vietnam

Photo: Fundação de Medicina Tropical

Endemic countries in South America meet to discuss new tools for malaria elimination

Photo: Anna Wang/MMV

Thailand becomes first malaria-endemic country in Asia-Pacific to approve tafenoquine for radical cure of P. vivax malaria

Photo: Damien Schumann/MMV

Request for Proposal - Development of low dose primaquine tablets in a child-friendly formulation

Photo: Anna Wang/MMV

World Malaria report 2019 launched

Photo: MMV

Country leaders pledge to boost malaria innovation and access to new and existing antimalarials

Photo: Fundação de Medicina Tropical

Brazil becomes first malaria-endemic country to approve single-dose tafenoquine (Kozenis) for radical cure of P. vivax malaria

Pages

1

Events